Burning Rock Biotech Limited has entered a collaboration with Bayer to develop next-generation sequencing (NGS)-based companion diagnostic assays (CDx), aiming to provide diagnostic methods to enable treatment choice for patients with cancer in China while driving innovation and development in cancer therapy.   This collaboration will focus on the development of companion diagnostic products in China, jointly developing NGS-based CDx for Bayer’s growing portfolio of precision cancer ther...